WuXi Biologics and Vir Biotechnology Collaborate for the Global Development of Antibodies Against COVID-19
Shots:
- The companies will jointly develop- manufacture & commercialize Vir's Ab. WuXi Biologics will conduct cell-line development- process & formulation development and initial manufacturing for clinical development
- Following the regulatory approvals- Wuxi Biologics to get rights to commercialize therapies in Greater China while Vir retain WW commercial rights for the therapies
- The collaboration accelerates the advancement of mAb against the global threat of COVID-19. Vir’s platform is used to identify rare Abs from survivor- treating rapidly evolving or previously untreatable pathogens via direct pathogen neutralization and immune system stimulation
Click here to read full press release/ article | Ref: PRNewswire | Image: Wuxi Biologics
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com